Abivax

DGAP-News: Abivax 2019 Financial Results and Operations Update

Monday, March 16, 2020 - 7:01pm

The observations confirmed the preliminary positive results on safety and tolerability of ABX464 along with a first evidence of its excellent long-term efficacy.

Key Points: 
  • The observations confirmed the preliminary positive results on safety and tolerability of ABX464 along with a first evidence of its excellent long-term efficacy.
  • Based on the encouraging results from the Phase 2a induction and maintenance trials, Abivax initiated a Phase 2b study, ABX464-103, in UC and enrolled the first patient in August 2019.
  • Top line results from this trial are expected in Q4 2020.
  • Abivax is currently planning for a start of the enrollment of patients in the second half of 2020.

Innovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates

Friday, December 13, 2019 - 2:30pm

The study is to be the first in a series of clinical trials, as part of the Companys Ulcerative Colitis (UC) clinical program.

Key Points: 
  • The study is to be the first in a series of clinical trials, as part of the Companys Ulcerative Colitis (UC) clinical program.
  • The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources.
  • Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS).
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.

Ulcerative Colitis Clinical Trial Pipeline Highlights, 2019 Market Report - ResearchAndMarkets.com

Thursday, June 6, 2019 - 4:00pm

The "Global Ulcerative Colitis Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ulcerative Colitis Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Ulcerative Colitis Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Ulcerative Colitis market.
  • It covers emerging therapies for Ulcerative Colitis in active clinical development stages including early and late stage clinical trials.
  • The report provides Ulcerative Colitis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.